Paxlovid-Induced Tacrolimus Toxicity in the Treatment of COVID-19: A Case Report.

Authors

Stephanie Michael, OhioHealth
Rachel Heilbronner, OhioHealth
Christopher M Lloyd, OhioHealth
Howard W Levitin, OhioHealth

Document Type

Article

Publication Title

Cureus

Abstract

Paxlovid^TM (nirmaltrelvir/ritonavir) received emergency use authorization from the Food and Drug Administration (FDA) in December 2021 to treat coronavirus disease 2019 (COVID-19). Given the actions of Paxlovid on cytochrome P450-3A4 (CYP3A4) enzymes, it is imperative to check for potential drug-drug interactions before prescribing. We describe a case in which the common emergency department presentation of generalized weakness was found to be caused by interactions between Paxlovid and a patient's home medications resulting in tacrolimus toxicity.

First Page

35489

Last Page

35489

DOI

10.7759/cureus.35489

Publication Date

2-1-2023

Recommended Citation

Michael S, Heilbronner R, Lloyd CM, Levitin HW. Paxlovid-Induced Tacrolimus Toxicity in the Treatment of COVID-19: A Case Report. Cureus. 2023 Feb 26;15(2):e35489. doi: 10.7759/cureus.35489. PMID: 36999105; PMCID: PMC10046481.